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Objective: The objective of this systematic review and meta-analysis was to compare the efficacy of three available
treatments for acute iliofemoral deep vein thrombosis (DVT): systemic anticoagulation, surgical thrombectomy, and
catheter-directed thrombolysis.
Methods: We searched electronic databases (MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science, and Scopus)
and sought additional references from experts. Eligible studies enrolled participants with acute iliofemoral DVT and
measured the outcomes of interest. Reviewers working independently in duplicate extracted study characteristics, quality,
and outcome data (death, pulmonary embolism, local complications, hemorrhagic complications, postthrombotic
syndrome, pain, quality of life, and surrogate markers of venous function such as valve competence and patency). We
pooled relative risks (RRs) from each study using the random effects model and estimated the 95% confidence intervals
(CIs). Bayesian indirect comparison techniques were used to compare thrombectomy to catheter-directed thrombolysis.
Results: We found 15 unique studies that fulfilled eligibility criteria. When compared to systemic anticoagulation,
thrombectomy was associated with a statistically significant reduction in the risk of developing postthrombotic syndrome
(RR, 0.67; 95% CI, 0.52-0.87), venous reflux (RR, 0.68; 95% CI, 0.46-0.99), and a trend for reduction in the risk of
venous obstruction (RR, 0.84; 95% CI, 0.60-1.19). When compared to systemic anticoagulation, pharmacologic
catheter-directed thrombolysis was associated with statistically significant reduction in the risk of postthrombotic
syndrome (RR, 0.19; 95% CI, 0.07-0.48), venous obstruction (RR, 0.38; 95% CI, 0.18-0.37), and a trend for reduction
in the risk of venous reflux (RR, 0.39; 95% CI, 0.16-1.00). Overall, the quality of evidence was low; downgraded due to
the observational nature of the majority of studies, lack of comparability of study cohorts at baseline, loss to follow-up,
imprecision, and indirectness of outcomes (surrogacy). There were insufficient data to compare the outcomes of
thrombectomy to catheter-directed thrombolysis.
Conclusions: Low-quality evidence suggests that surgical thrombectomy decreases the incidence of postthrombotic
syndrome and venous reflux. Catheter-directed pharmacologic thrombolysis decreases the incidence of postthrombotic
syndrome and venous obstruction. (J Vasc Surg 2012;55:1463-73.)
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iAcute iliofemoral deep vein thrombosis (DVT) is a
major cause of morbidity that will affect approximately 5%
of people at some point in their lives.1 Standard treatment
is with systemic anticoagulation to decrease the propaga-
tion of the thrombus and prevent pulmonary embolism
(PE).2,3 Long-term complications include recurrent
thrombosis and postthrombotic syndrome. Despite sys-
temic anticoagulation, over half of the patients with a DVT
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doi:10.1016/j.jvs.2011.12.082ill develop postthrombotic syndrome with symptoms of
ain, edema, skin changes, or ulceration.4-6
Surgical thrombectomy and catheter-directed throm-
olysis have been used in the treatment of acute arterial and
enous thrombotic conditions, including iliofemoral DVT.
eeking to provide guidance in this area, the Society for
ascular Surgery (SVS) has partnered with the American
enous Forum (AVF) and formed amultispecialty commit-
ee to formulate evidence-based clinical practice guidelines
or the care of patients with acute iliofemoral DVT. To
upport the formulation of these guidelines, we conducted
systematic review of the literature to identify and summa-
ize the best available evidence about the efficacy of catheter-
irected thrombolysis, surgical thrombectomy, and systemic
nticoagulation for the treatment of iliofemoral DVT.
ETHODS
The report of this protocol-driven systematic review
as approved by the Venous Guidelines Committee of the
VS/AVF and is in adherence with the Quality of Report-
ng of Meta-analyses (QUOROM) standards for reporting
ystematic reviews of randomized clinical trials and report-
ng Meta-analyses of Observational Studies in Epidemiol-
gy (MOOSE).7,8 The quality of evidence was rated using
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ment, and Evaluation (GRADE) methods.9
Eligibility criteria: Eligible studies were randomized
clinical trials and cohort studies that enrolled participants
with acute iliofemoral DVT. To allow for the comparative
effectiveness of these treatments, included studies had to
enroll patients who were treated with at least two of
the following three treatments: surgical thrombectomy,
catheter-directed thrombolysis, or conservative manage-
ment with traditional anticoagulation. We included studies
that measured the outcomes of interest (death, pulmonary
embolism, local complications, hemorrhagic complica-
tions, postthrombotic syndrome, pain, and quality of life).
We also collected data about the surrogate outcomes of
venous valve competency and vein patency. Studies were
included regardless of their language, sample size, type of
thrombolytic used, surgical technique, or duration of pa-
tient follow-up. Single cohort studies (ie, studies in which
all patients received the same treatment without concurrent
comparison groups) were excluded. We also excluded stud-
ies of systemic thrombolysis considering the increased risk
of bleeding and incomplete thrombolysis known to be
associated with this procedure.10
Study identification: An expert reference librarian
(P.E.) designed and conducted the electronic search strat-
egy with input from study investigators with expertise in
conducting systematic reviews. To identify eligible studies,
we searched electronic databases (MEDLINE, EMBASE,
Cochrane CENTRAL, Web of Science, and Scopus)
through February 2008 and monitored the literature for
new publications thereafter. We also sought references
from experts, bibliographies of included trials, and the
Institute for Scientific Information Science Citation Index
575 Potentially relevant Article
by search 
87 Articles selected for full tex
17 Articles Fulfilled eligibility cr
-15 studies
-2 systematic reviews
10 Thrombectomy vs. anticoagulation
7 reported outcome of death
4 reported outcome of pulmonary embolism
9 reported outcome of postthrombotic syndrome
4 reported outcome of venous obstruction
5 reported outcome of reflux
5 C
2 re
2 re
3 re
4 re
3 re
Fig 1. The procfor publications that cited included studies. A combination wf subject headings and text words were used to describe the
ondition and the treatment. The results were limited to
linical trials, meta-analyses, retrospective and prospective
tudies, and treatment outcomes. The Cochrane Central
egister of Clinical Trials was searched using both subject
eadings and text words. Web of Science and Scopus were
earched using text words. The detailed search strategy is
vailable from the authors upon request.
Data collection: Teams of two reviewers working in-
ependently and using a standardized form extracted data
rom all eligible studies. We extracted descriptive data
study size, number of patients in each arm, patients’ age,
hrombophilia risk factors, DVT location, time elapsed
etween onset of symptoms and intervention, and descrip-
ion of the intervention and control procedure), method-
logical data (elements of bias protection in randomized
rials such as allocation concealment, blinding, and propor-
ions of patients lost to follow-up, and elements of bias
rotection in observational studies such as the prognostic
omparability of the two study groups, ascertainment of ex-
osure and outcome, and blinding of outcome assessors), and
utcome data (death, pulmonary embolism, local complica-
ions, hemorrhagic complications, postthrombotic syndrome,
ain, quality of life, and surrogatemarkers of venous function,
ncluding valve competence and patency). We attempted to
ontact authors of all included studies by e-mail to obtain
issing data.
Statistical analyses. To conduct meta-analysis, we
ooled relative risks (RRs) for dichotomous outcomes from
ach study using the DerSimonian-Laird random effects
odel and estimated the 95% confidence intervals (CIs) for
ach outcome to reflect the uncertainty of point estimates
f effect.11 For continuous outcomes, we estimated the
tified 
488 Excluded after screening of 
abstracts 
val
70 Excluded after full text screening
21     Not original articles
29     No concurrent control
20     Irrelevant population or interventions
r-directed thrombolysis  vs. anticoagulation
d outcome of death
d outcome of pulmonary embolism
d outcome of postthrombotic syndrome
d outcome of venous obstruction
d outcome of reflux
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that is due to heterogeneity rather than chance (ie, the
percentage of variability in treatment effects across trials
that is not due to chance or random error, but rather due to
real differences in study patients, design or interven-
tions).12 Statistical analysis was conducted using Compre-
hensive Meta-Analysis software, version 2 (Biostat, Engle-
wood, NJ). Anticipating that few if any studies would have
directly compared catheter-directed thrombolysis and sur-
gical thrombectomy, we explored Bayesian indirect com-
Relative risk Lower Upper 
limit limit Thrombe
Matsubara, 1976 0.44 0.16 1.21 3 / 
Postthrombotic 
syndrome
Plate, 1984 0.63 0.44 0.90 14 /
Torngren,1996 0.83 0.50 1.40 14 /
Stiegler, 1987 0.65 0.44 0.95 22 /
Weaver, 1988 0.83 0.18 3.96 1 /
Ganger, 1989 0.44 0.24 0.80 8 / 
Hold, 1992 0.93 0.66 1.29 18 /
Sato, 1992 0.18 0.01 2.46 0 /
0.67 0.52 0.87
Plate, 1984
Venous Reflux
0.65 0.40 1.05 11 /
Torngren,1996 1.02 0.50 2.06 11 /
Fasolini, 1985 0.96 0.53 1.72 9 / 
Ganger, 1989 0.35 0.17 0.72 6 / 
Hamilton 1996 0 14 0 01 2 38 0 /
Pooled RR
, . . .  
0.68 0.47 0.99
Plate, 1984
Venous
obstruction
0.51 0.27 0.96 8 / 
Torngren,1996 2.22 0.66 7.50 8 / 
Fasolini, 1985 1.16 0.74 1.82 12 /
Stiegler, 1987 0.71 0.57 0.90 38 /
0.83 0.59 1.16
Pooled RR
Pooled RR
Fig 2. Meta-analysis of surgical thrombectomy vs syst
risk.
Outcome
RR Lower Upp
limit lim
AbuRahma, 2001 0.32 0.13 0.
Markevicius, 2004 0.10 0.03 0.
0.18 0.05 0.
Markevicius, 2004 0.20 0.11 0.
Elsharawy, 2002 0.27 0.06 1.
Enden, 2009 0.91 0.67 1.
0.39 0.16 1.
AbuRahma, 2001 0.56 0.33 0.
Markevicius, 2004 0.07 0.01 0.
Postthrombotic syndrome
Venous reflux
Pooled RR
Pooled RR
Elsharawy, 2002 0.31 0.15 0.
Enden, 2009 0.56 0.37 0.
0.38 0.17 0.
Venous obstruction
Pooled RR
Fig 3. Meta-analysis of pharmacologic catheter-directe
interval; RR, relative risk.parisons13 to make inferences on the difference of the treatment effects between the two interventions that may
ot have been compared head-to-head. We calculated the
osterior median with 95% credible intervals (CrIs) of RRs
or comparing the treatment effects on outcomes of inter-
st. Bayesian analysis was conducted using WinBUGS soft-
are, version 1.4.3 (MRC Biostatistics Unit, Cambridge,
K).
UBGROUP AND SENSITIVITY ANALYSES
Our a priori hypotheses to explore subgroup interac-
IC %59 dna ksir evitaleRlatoT / 
Anticoagulation
36 / 64
25 / 27
14 / 25
62 / 124
3 / 5
19 / 25
64 / 102
31 / 45
20 / 27
9 / 25
10 / 17
18 / 25
2 / 4  
17 / 26
3 / 25
11 / 17
97 / 124
0.01 0.1 1 10 100
Favors thrombectomy Favors anticoagulation
anticoagulation. CI, Confidence interval; RR, relative
Events / Total
lysis anticoag
Relative risk and 95% CI
4 / 18 23 / 33
3 / 43 47 / 64
7 / 61 70 / 97
11 / 60 84 / 90
2 / 18 7 / 17
30 / 50 35 / 53
43 / 128 126 / 160
8 / 18 26 / 33
1 / 60 21 / 90
5 / 18 15 / 17
18 / 50 34 / 53
32 / 146 96 / 193
0.1 0.2 0.5 1 2
Favors thrombolysis Favors anticoagulation
ombolysis vs systemic anticoagulation. CI, ConfidencestnevE
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First author,
year Population Age (years)a
Thrombophilia
(%)a
Postoperative
(%)a
Pregnancy
(%)a
Cancer
(%)a DVT description
Matsubara
197627
All DVT patients referred
to surgical service
Range (18-79) NR 41% 5% 2% Acute and chronic
iliofemoral
Plate 198422 General population 63 NR 11% 5% 17% Acute iliofemoral with
proximal extension
above the inguinal
ligament but below
caval bifurcation
Fasolini
198519
General population 63 NR NR NR NR Iliofemoral
Stiegler
198726
General population NR NR NR NR NR Iliofemoral
Weaver
198818
Phlegmasia cerulea dolens
with or without venous
gangrene
59 (26-83) 6% 0% 0% 44% Unclear
Gänger
198928
General population 30 NR NR NR NR Acute iliofemoral
Hold
199230
General population 52.5 NR NR NR 9% Acute DVT; iliac 
10, iliofemoral 
53, femoral  7,
femoropopliteal 
47, popliteal  41
Sato 199232 General population 50 NR NR NR NR Acute DVT in the
lower extremities
Hamilton
199625
Renal transplant patients
with ipsilateral
iliofemoral thrombosis
with or without
allograft failure
29.6 and 37.5 NR NR NR NR Acute iliofemoral
Törngren
199633
Pregnant/postpartum
women
28 12% NR 100% NR Acute iliofemoral
AbuRahma
200115
Consecutive patients with
DVT
48 17% and 21% 17% and 27% NR 22% and
21%
Extensive iliofemoral
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Intervention No Control group No.
Duration of
symptoms Postprocedure surveillance Follow-up
Thrombectomy 13 IV heparin, urokinase,
elevation,
compression;
followed by warfarin
82 6 hours to 14 days;
in few chronic
cases
thrombectomy
was done up to 6
years after DVT
Questionnaire and
interview. Venography
done only before
thrombectomy, not after
6 months
Thrombectomy with
temporary AV fistula
31 Heparin for 5-7 days
followed by warfarin
for 6 months
32 2 days Phlebography, Doppler
US and clinical
examination at 6
months
6 months, 5 and
10 years
Thrombectomy 18 IV heparin, some
patients may have had
thrombolysis-unclear
17 10-13 days Examination and
radionuclear
phlebography
10 years
Thrombectomy 68 Heparin IV, aPTT 80-
120 seconds, duration
of treatment NR
124 NR Examination and
phlebography at 8 and
180 days; examination
at 90 days
6 months
Thrombectomy without
fistula
3 (ext) Heparin IV, aPTT
target twice control,
one patient received
streptokinase as well
13 (14
ext.)
2 days (1 hour-7
days)
Physical examination Thrombectomy
3 months;
controls 9
years
Thrombectomy followed
by heparin and
coumarin to quick
value of 25%-30%,
compression stockings
for 2-6 months
31 Heparin then warfarin
for at least 6 months,
compression stockings
24 3 days Self report, examination,
strain gauge
plethysmography,
Doppler sonography,
duplex sonography at
last f/u
7.7 years
Thrombectomy with or
without AV fistula and
balloon venoplasty
31 Anticoagulation and
compression therapy
102 7 days Examination, self
reported satisfaction,
and outflow
plethysmography at
one visit (18-54
months)
18-54 months
Thrombectomy by
Fogarty catheter
3 IV heparin and
urokinase for 6-10
days followed by
warfarin
45 (ext) Less than 3 days for
thrombectomy
group; control
group is split into
less than a week
andmore than a
week
NR 12 months
Thrombectomy
associated with renal
allograft nephrectomy,
no anticoagulation
8 Heparin for 7-10 days
followed by 3 months
warfarin
7 Postoperative days
(not symptom
onset):
thrombectomy
2.1 days and
controls 9.6 days
Photoplethysmography
and Doppler at one
f/u visit
1-5 years
Thrombectomy 30 IV heparin, followed by
SC heparin; oral
anticoagulants after
delivery; total duration
of treatment 3-12
months
25 Thrombectomy 4
days; control 8
days
Clinical examination,
color duplex
ultrasound and venous
strain-gauge
plethysmography.
9 years
Catheter-based
thrombolysis with
urokinase later changed
to rt-PA. Angioplasty
and stenting if residual
stenosis. Concurrent
systemic heparin IV
followed by warfarin for
6-12months (INR goal
18 Heparin IV, aPTT
target twice control,
followed by warfarin
for 6-12 months,
INR target 2.0-3.0
33 3.6 days for
thrombolysis
and 3.8 days for
controls (range,
1-11 for the
whole series)
All patients underwent
venous duplex imaging
at 30 days, 3 months,
6 months, and every 6
months thereafter
7.5 years2-3)
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protection measures, patient characteristics (age, whether
patients have risk factors for recurrent DVT), duration
between the onset of DVT symptoms and delivery of
intervention (a week or less vs more than a week), and the
length of study follow-up (a year or less vs more than a
year). We tested the hypotheses of a subgroup effect using
a test of interaction.14 We also conducted meta-regression
to assess the correlation between the effect size and the
proportion of patients lost to follow-up, a measure of study
quality. In addition, we conducted a sensitivity analysis
excluding studies in which thrombosis was not confined to
the iliofemoral segment.
RESULTS
Study identification. Fig 1 depicts our search and selec-
tion procedures. We found 22 eligible publications15-34 that
represented 15 unique studies and 2 systematic reviews.35,36
Authors of four studies responded to our queries.16,18,22,29 Ta-
ble I summarizes the characteristics of the included studies.
Ten studies compared thrombectomy to systemic anti-
coagulation and five other studies compared pharmaco-
logic catheter-directed thrombolysis to systemic anticoag-
ulation. These studies enrolled 1186 participants, with a
mean sample size of 77 and mean duration of follow-up of
55.2 months (range, 3-120 months). Three of the final 14
studies were translated to English before data extrac-
tion.19,26,32
We excluded two cohorts from the final analysis (one of
three arms of a study by Hold et al30 and the two arms of
Tsapogas et al37) because thrombolysis in these patients
was systemically administered.
Methodological quality. Table II summarizes the
Table I. Continued.
First author,
year Population Age (years)a
Throm
(%
Comerota
200216
Patients hospitalized for
DVT
55 and 61 N
Markevicius
200431
NR NR N
Elsharawy
200229
Female, general
population, no
contraindications for
thrombolysis
44 and 49 N
Enden
200934
First-time objectively
verified iliofemoral
DVT ( popliteal and
calf vein thrombosis)
52 4
aPTT, Activated partial thromboplastin time; AV, arteriovenous; DVT, deep
ratio; IV, intravenous; LMWH, low-molecular-weight heparin; NR, not rep
ultrasound.
aIf patients’ demographics are reported to be different between intervention a
represents the control group.
bFollow-up was 12 months for recanalization and competence outcomes anmethodological quality of the included studies. Reviewers nad adequate chance-adjusted agreement in judging study
uality (k .81-1.00). Overall, the quality of evidence was
ow. The quality of evidence was downgraded due to the
ack of randomization in most studies, lack of comparability
f study cohorts at baseline (patients allocated to anticoag-
lation often presented late or had less severe symptoms),
nd poor follow-up rate (the proportion of patients lost
o follow-up was less than 10% in only three of the
ncluded studies). In general, outcome ascertainment
as adequate in most trials (ie, postthrombotic syn-
rome, death, and pulmonary embolism [PE] were docu-
ented bymedical record review and physical examination;
enous obstruction and reflux were documented by venous
uplex scan imaging). The evaluation of outcomes was
ostly unblinded.
eta-analysis
Surgical thrombectomy. When compared to sys-
emic anticoagulation, thrombectomywas associated with a
tatistically significant reduction in the risk of developing
ostthrombotic syndrome (RR, 0.67; 95% CI, 0.52-0.87;
2 0%) and venous reflux (RR, 0.68; 95% CI, 0.46-0.99;
2  43%), and a trend for reduction in the risk of venous
bstruction (RR, 0.84; 95% CI, 0.60-1.19; I2  66%).
esults are depicted in Fig 2.
In the study with the longest follow-up, Plate et al20
emonstrated that the superiority of thrombectomy over
nticoagulation persisted after 10 years. The incidence of
aving any symptoms in medically treated patients was 88%
ompared with 62% in the surgical group; the incidence of
evere symptoms in medically treated patients was 76%
ompared with 46% in the surgical group. The competency
f femoropopliteal valves was investigated by duplex scan-
lia Postoperative
(%)a
Pregnancy
(%)a
Cancer
(%)a DVT description
NR NR NR Iliofemoral
NR NR NR Acute
proximal/femoral
3% 0 11% Acute (10 days)
iliofemoral
0% 4% 3% Iliofemoral DVT and
symptoms 21 days
thrombosis; ext., extremity; f/u, follow-up; INR, international normalized
PA, popliteal artery; SC, subcutaneous; UFH, unfractionated heparin; US,
trol groups, the first value represents the intervention group and the second
onths for quality of life and postthrombotic syndrome.bophi
)a
R
R
R
0%
vein
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nd coning and the incidence of reflux in the femoral vein after
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gery; the incidence of reflux in the popliteal veins was 57%
in medically treated patients compared with 22% in the
surgical group.20 These results were imprecise due to the
small number of events and sample size.
Meta-analysis demonstrated no significant effects on
the outcomes of death (RR, 0.80; 95% CI, 0.10-6.22; I2
84), PE (RR, 0.56; 95% CI, 0.08-4.18; I2  0), or recur-
rence of DVT (RR, 0.69; 95% CI, 0.24-2.01; one study).
Data were insufficient to conduct meta-analysis on the
quality of life outcome. In terms of satisfaction with treat-
ment, Hold et al30 reported 31 patients who underwent
thrombectomy, 25 patients who underwent catheter-
directed thrombolysis with streptokinase, and 102 patients
who underwent treatment with heparin and compression
wrapping. Patients were satisfied with the results of their
treatment in 39%, 20%, and 39% of the cases; respectively
(P  .5).
Catheter-directed thrombolysis. When compared to
systemic anticoagulation, pharmacologic catheter-directed
thrombolysis was associated with statistically significant
reduction in the risk of postthrombotic syndrome (RR,
0.19; 95% CI, 0.07-0.48; I2  64%) and venous obstruc-
tion (RR, 0.38; 95% CI, 0.18-0.37; I2 46%), and a trend
for reduction in the risk of venous reflux (RR, 0.39; 95%
CI, 0.16-1.00; I2  92%). Results are depicted in Fig 3.
Data regarding patient-important outcomes such as
death, PE, recurrence of DVT, hospitalization, and dis-
ability, were inconclusive and sparse. In terms of quality
of life measurements, Comerota et al16,17 retrospectively
identified and mailed a questionnaire to 98 patients who
Table I. Continued.
Intervention No Control group N
Catheter directed
thrombolysis
(urokinase)
68 Heparin converted to
oral anticoagulation
3
Catheter directed
thrombolysis
60 Conventional
anticoagulation for 12
months
9
Catheter directed
streptokinase; pulse
spray followed by
100,000 u/hour
infusion
Heparin followed by
warfarin, target INR
of 2.0; duration of
treatment NR
1
Bolus and infusion of
UFH; then 20 mg of
alteplase in 500 mL
0.9% NaCl was
infused for a maximal
duration of 96 hours
50 LMWH followed by
warfarin for 6
months with a target
INR 2.0-3.0
5had an iliofemoral DVT treated at least 6 months earlier. vixty-eight patients were treated with catheter-directed
hrombolysis and 30 patients were treated with systemic
nticoagulation. Patients treated with catheter-directed
hrombolysis reported less health distress (P  .04) and
ewer overall symptoms (P  .04) at a mean follow-up
ime of 22 months.
The first systematic review by Dasari et al35 summa-
ized a total of eight case series of pharmacomechanical
hrombolysis (n  2528; 1998-2009) for the treatment of
cute and chronic DVTs (lower extremity symptomatic
VTs constituted 80% of the cases). Procedural success
ate averaged 59% to 100%. Catheter-directed thrombolysis
as used as an adjunct in 16% to 53% of the cases. No
eaths or major bleeding complications were reported. The
econd systematic review by Karthikesalingam et al36 eval-
ated percutaneous mechanical thrombectomy and in-
luded six retrospective case series that reported the use of
heolytic, rotational, or ultrasound scan-assisted devices in
81 patients. Success rate of 82% to 100% was reported
ith grade II or III lysis in 83% to 100% of patients with no
eported procedure-related deaths or strokes and 1%
ncidence of symptomatic PE. Bleeding complications re-
uiring transfusion were reported in 7.5% of the patients.
Indirect comparison (thrombectomy vs catheter-
ased lysis). When compared to surgical thrombectomy,
atheter-directed thrombolysis was associated with insig-
ificant reduction in the risk of postthrombotic syndrome
RR, 0.33; 95% CrI, 0.00-2.28), venous reflux (RR, 0.44;
5% CrI, 0.05-2.10), and venous obstruction (RR, 0.30;
5% CrI, 0.01-2.13). These estimates were associated with
Duration of
symptoms Postprocedure surveillance Follow-up
NR Mailed survey at 16 and
22 months after DVT
treatment
22 months
NR Duplex at 1, 3, 9, 12
months and venography
at 6 months
16 monthsb
Thrombolysis 3
days; controls
6 days
F/u at 6 weeks, 3 and 6
months. At 6months
f/u: duplex US,
photoplethysmography
and air-plethysmography
6 months
21 days Ultrasound and air
plethysmography
6 monthso.
0
0
7
3ery wide CrIs.
d
p
o
t
t
n
t
s
s
e
o
t
l
o
tudies
studie
JOURNAL OF VASCULAR SURGERY
May 20121470 Casey et alOther adverse events. Adverse events overall were
poorly reported. Törngren et al33 reported no intracranial
hemorrhage in either study arm, one localized bleeding in
the thrombectomy group, and one patient with hematuria
in the systemic anticoagulation group. Plate et al22 re-
ported one case of gangrenous leg that led to an above-the-
knee amputation in the surgical thrombectomy group.
Weaver et al18 reported a series of patients with phlegmasia
cerulea dolens. In the group treated with surgical throm-
bectomy, one patient required below-the-knee amputa-
tion; there were two wound seromas, and one patient
treated with heparin after thrombectomy developed
thrombocytopenia. One patient in the thrombolytic group
failed therapy, underwent an unsuccessful thrombectomy,
and subsequently developed contralateral iliofemoral arterial
Table II. Study quality
First author, year Study design Funding sourc
Matsubara 197627 Nonrandomized
prospective
NR
Plate 198422 Randomized NR
Fasolini 198519 Nonrandomized NR
Stiegler 198726 Nonrandomized NR
Weaver 198818 Nonrandomized
retrospective
NR
Gänger 198928 Nonrandomized
retrospective
NR
Hold 199230 Nonrandomized
retrospective
Not-for-profit
Sato 199232 Nonrandomized
retrospective
NR
Hamilton 199625 Nonrandomized
retrospective
NR
Törngren 199633 Nonrandomized
retrospective
Not-for-profit
AbuRahma 200115 Nonrandomized
prospective
NR
Comerota 200216 Nonrandomized
retrospective
Included for-pro
sources
Elsharawy 200229 Randomized NR
Markevicius 200431 Nonrandomized
prospective
NR
Enden 200934 Randomized Not-for-profit
DVT, Deep venous thrombosis; NR, not reported; NA, nonapplicable.
aAllocation concealment assessed as a quality measure only in randomized s
bGroup comparability assessed as a quality measure only in nonrandomizedocclusion. In the systemic anticoagulation group, one patient beveloped mesenteric thrombosis. AbuRahma et al15 re-
orted two episodes of major bleeding and three episodes
f minor bleeding in both the thrombolysis and the sys-
emic anticoagulation groups. Elsharawy et al29 reported
hat three patients developed fever after thrombolysis with
o major bleeding as compared to no reported complica-
ion in the group treated with systemic anticoagulation.
Subgroup and sensitivity analyses. The results of
ubgroup analyses of thrombectomy vs anticoagulation are
ummarized in Table III. The only significant subgroup
ffect was for patency follow-up duration. The superiority
f thrombectomy over anticoagulation in maintaining pa-
ency was significant in studies that followed patients for
ess than a year, compared with studies with follow-up for
ver a year. We found no significant effect of the duration
Proportion of lost to follow-up
Were patients lost to
follow-up because of
suffering outcome?
7.7% (one patient) for
thrombolysis; 23.2% (18
patients) for conservative
NR
20% NR
6% No
NR No
25% NR
23% in thrombectomy group, 0%
in conventional group
NR
0% NR
NR NR
27% No
23% (thrombectomy) 32%
(anticoagulation)
NR
37% NR
38% NR
0% NR
NR NR
1% No
.
s.e
fitetween the onset of symptoms and the time of delivering
o
a
b
c
o
c
t
s
s
t
D
a
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Volume 55, Number 5 Casey et al 1471intervention on the relative estimates of the outcomes of
patency, reflux, or postthrombotic syndrome. Some of the
included studies suggested that thrombectomy was more
effective if delivered early (within 3 days of the onset of
symptoms)28 and that anticoagulation was more likely to
cause symptom relief if administered within 7 days of the
onset of symptoms.32 Therefore, it seems that earlier inter-
vention may be more beneficial, although no high-quality
evidence is available to recommend an optimal time interval
for intervention.
Meta-regression demonstrated no significant association
between the effect size and the proportion of patients lost to
follow-up for the outcomes of reflux (P .23), patency (P
.84), and postthrombotic syndrome (P .13).
The exclusion of thrombectomy studies that did not
Table II. Continued.
Were outcome assessors or data collectors
blinded? Outcome ascertainm
No or NR No (eg, self report)
No or NR Yes (medical record
review/examination/
No or NR Yes, examination and nu
phlebography
No or NR Yes, examination and ph
No or NR Yes (medical record
review/examination/
No or NR Yes (medical record
review/examination/
No or NR Yes (medical record
review/examination/
NR NR
No or NR Yes (medical record
review/examination/
No or NR Yes (medical record
review/examination/
No or NR Yes (medical record
review/examination/
No or NR Yes (medical record
review/examination/
Yes, images assessed by blinded vascular
imaging panel
Yes (medical record
review/examination/
No or NR Yes (medical record
review/examination/
Yes Yes (medical record
review/examination/explicitly state that thrombosis was confined to the iliofem- Dral segment18,30,32 led to results similar to that of themain
nalysis. The outcomes of patency and reflux do not change
ecause these three studies did not report these two out-
omes and did not contribute to the pooled estimate. The
utcome of postthrombotic syndrome changes slightly but
ontinues to show statistically significant effect favoring
hrombectomy (RR, 0.63; 95% CI, 0.51-0.78; six studies).
Due to limited data and small number of studies,
ubgroup analyses and sensitivity analyses were not fea-
ible in catheter-directed thrombolysis vs anticoagula-
ion studies.
ISCUSSION
In our study, we conducted a systematic review andmeta-
nalyses comparing three treatments for acute iliofemoral
dequate?
Allocation
concealed?a Study arms comparable?b
NA No, patients were allocated to control
group if their symptoms were mild
ler)
No NA
NA No or NR
graphy NA No or NR
ler)
NA No or NR
ler)
NA Yes, control group matched to
surgical group for follow-up time,
age, duration of symptoms, extent
of DVT
ler)
NA No, only patients with symptoms 7
days considered for lysis or
thrombectomy
NA No or NR
ler)
NA No, anticoagulation patients were
older and presented later;
thrombectomy patients presumed
to have a technical problem with
allograft
ler)
NA Yes
ler)
NA Yes, study arms were balanced for
malignancy, trauma/post-op, and
hypercoagulability
ler)
NA Yes, adjusted using propensity scores
(education, marital status, age) and
number of days since
hospitalization.
ler)
No NA
ler)
NA NR
ler)
No Yesent a
Dopp
clear
lebo
Dopp
Dopp
Dopp
Dopp
Dopp
Dopp
Dopp
Dopp
Dopp
DoppVT. Our results show that compared with systemic antico-
a
e
a
r
s
a
t
d
t
p
t
i
c
c
C
t
a
d
d
A
r
p
A
C
A
D
W
C
F
S
O
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had lower incidence of postthrombotic syndrome and were
more likely to have competent venous valves. There was also a
trend toward greater vein patency with thrombectomy.When
pharmacologic catheter-directed thrombolysis was compared
to systemic anticoagulation, similar results were found. Phar-
macologic catheter-directed thrombolysis was associated with
lower incidence of postthrombotic syndrome and increased
venous competency and greater vein patency. Pharmaco-
mechanical thrombolysis was associated with a success rate of
59% to 100%. However, this evidence is indirect considering
that these studies were not exclusively done in the setting of
acute iliofemoral DVT.
Across all study procedures, there were insufficient data
to assess patient-important outcomes such as death, PE,
and quality of life. The indirect comparison of catheter-
directed thrombolysis vs surgical thrombectomy yielded
extremely imprecise estimates. Considering the temporal
difference with no overlap as to when these studies were
conducted (venous thrombectomy 1987-1996 and cathe-
ter thrombolysis 2001-2009), we are unable to reliably
determine the relative the efficacy of these two procedures.
Limitations and strengths of this review. The infer-
ences from this review are limited by the quality of the
evidence available in the published literature. The quality of
evidence supporting thrombectomy or catheter-directed
thrombolysis is downgraded due to methodological limita-
tions of the primary studies (lack of bias protection mea-
sures); lack of comparability of study cohorts at baseline;
indirectness of evidence (for outcomes such as vein patency
and valve competency, which are surrogate outcomes); and
imprecision of the magnitude of treatment effect on pa-
tient-important outcomes (CIs are wide enough to include
important benefit and harm from systemic anticoagula-
tion).9 In addition, publication and reporting biases are
difficult to detect (few studies and inconsistent results) and
they usually create an impression in favor of newer and
more invasive technologies compared with traditional con-
Table III. Subgroup analyses (thrombectomy vs anticoag
Moderator No
Venous reflux
Symptoms less than a week before intervention
Symptoms a week or more before intervention
Follow-up length less than a year
Follow-up length a year or more
Venous obstruction
Symptoms less than a week before intervention
Symptoms a week or more before intervention
Follow-up length less than a year
Follow-up length a year or more
Postthrombotic syndrome
Symptoms less than a week before intervention
Symptoms a week or more before intervention
Follow-up length less than a year
Follow-up length a year or more
CI, Confidence interval; RR, relative risk.servative treatments. OThe strengths of this review are derived from having
focused question, an explicit protocol of review with
ligibility criteria for studies, and a thorough and system-
tic search strategy. We also used measures to decrease
eviewer bias such as having independent reviewers
elect, evaluate, and extract evidence in duplicate with
dequate reproducibility, and contacting authors of
he primary studies to obtain complete and accurate
ata.
Implications for research and practice. The implica-
ions for practice are discussed in the accompanying clinical
ractice guidelines by the Venous Guidelines Committee of
he SVS/AVF.38 Further head-to-head comparative stud-
es are needed to determine the relative efficacy and
ost-effectiveness of thrombectomy, pharmacomechani-
al, and pharmacologic catheter-directed thrombolysis.
ONCLUSIONS
Low-quality evidence suggests that surgical thrombec-
omy decreases the incidence of postthrombotic syndrome
nd venous reflux and that pharmacologic catheter-
irected thrombolysis decreases the incidence of reliably
etermine the relative syndrome and venous obstruction.
dditional rigorous research is required to determine the
elative efficacy of these technologies and their impact on
atient-important outcomes.
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